Insys Therapeutics, Inc. (INSY)

Trade INSY now with
8/9/2019 4:42:51 AM Hikma Pharma Inks Asset Purchase Agreement With Insys Therapeutics
7/3/2019 6:05:13 AM FDA Accepts NDA For INSYS Therapeutics' Naloxone Nasal Spray
6/10/2019 6:11:58 AM INSYS Files Voluntary Chapter 11 Cases; Plans To Continue Operations As Normal
4/15/2019 8:38:19 AM INSYS Therapeutics Appoints Andrew Long CEO
2/25/2019 6:12:37 AM INSYS Presents Poster Of Initial PK Study Of Comparative Bioavailability Of Epinephrine Nasal Spray And EpiPen
1/9/2019 6:04:34 AM INSYS Therapeutics Announces Results Of Dose-Finding PK Study For Epinephrine Nasal Spray For Treatment Of Anaphylaxis
12/18/2018 6:03:11 AM INSYS Therapeutics Announces Participation At FDA Advisory Committee Meeting Addressing The Co-Prescribing Of Naloxone
12/4/2018 6:04:48 AM INSYS Therapeutics Presents New Clinical Data From Long-Term Safety Study Of CBD Oral Solution
11/1/2018 6:15:25 AM INSYS Therapeutics Says PK Study Of Proprietary Intranasal Naloxone Spray Formulations Showed Distinctive PK Profile
10/10/2018 6:04:09 AM INSYS Therapeutics Adds Mark Nance To Its Senior Management Team As Chief Legal Officer And General Counsel
10/1/2018 6:06:09 AM INSYS Therapeutics Signs Definitive License Deal With Lunatus To Commercialize SUBSYS In Middle East
9/24/2018 6:04:23 AM INSYS Therapeutics Completes Initial Clinical Study Of Dronabinol Inhalation With Innovative Breath-Actuated Inhaler
9/4/2018 6:09:20 AM INSYS And UC San Diego’s Center For Medicinal Cannabis Research Expand Collaboration